Jet Milling and Fine Particle Size Reduction Patents
One filer, 402 families — the leader alone accounts for more filings than the next four combined, yet the top 5 still hold only 25.5% of all 3,856 records in scope. Filings ran from 144 in 2017 to a peak of 164 in 2018, then eased to 129 by 2024 (a 13% decline from the 2021 count of 149). Publication lags filing by roughly 18 months, so 2025 and 2026 figures — down to 16 recorded so far in 2026 — understate real filing activity and should not be read as a slowdown.
- 1ICEUTICA PTY LTD10.4%
- 2VECTURA LTD6.2%
- 3TEVA PHARMA IND LTD4.9%
- 4BOEHRINGER INGELHEIM PHARMA GMBH & CO KG2.2%
- 5COROMANDEL INT LTD1.8%
See the full jet milling and fine particle size reduction analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most jet milling patents?
One assignee leads the ranked field with 402 families, noticeably ahead of the fifth-ranked entrant at 68 and the tenth-ranked entrant at 52. Even so, the top 5 assignees combined account for only 25.5% of the 3,856 records in scope, and the top 10 for 32.5%, so leadership at the top does not translate into control of the field. Most of the ranking is made up of assignees with a small handful of families each, which points to a fragmented rather than consolidated landscape.
Is jet milling patent activity declining?
Filings peaked at 164 records in 2018 and eased to 129 by 2024, a 13% decline from the 2021 count of 149. That is a real cooling, but publication lags filing by roughly 18 months, so the very low counts shown for 2025 and 2026 (16 records so far) are simply incomplete, not evidence of a further drop. The more reliable read is a moderate pullback from a 2018 peak rather than an active abandonment of the technology.
Why do most jet milling patents classify under pharmaceutical codes?
In this dataset, 59.2% of records carry the A61K medicinal-preparations class and 18.7% carry A61P therapeutic-activity codes, while the core grinding-equipment class B02C appears in only 5.1% of records. That split reflects how jet milling and micronization are most often claimed jointly with the drug particle or formulation they produce, rather than as standalone mechanical process claims. A filer focused purely on mill hardware or process control is competing in a much thinner slice of the classified landscape than the headline pharma volume suggests.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Jet Milling and Fine Particle Size Reduction covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.